Simon Pfisterer

CSO, co-founder, Moncyte Ltd
Principal Investigator, University of Helsinki

[Simon Pfisterer @SimonPfisterer]

Extremely happy that our work got accepted in #ATVB! We functionally profiled 400 biobank samples, linking cellular lipid uptake, storage and handling to treatment outcomes of statin therapy and residual cardiovascular risk.
https://t.co/juNgqzoaVP

[Simon Pfisterer @SimonPfisterer]

At MONCYTE Health we are looking for a laboratory technician. Are you ready to join a vibrant and exciting team, pushing boundaries in precision medicine? Please apply!
More information can be found here:
https://t.co/IKMwHKZWJZ
The closing date for applications is: 30.11.2025

[Tamara Alagirova @TamaraAlagirova]

Honoured to have participated in the inaugural @WHXTech in Dubai. Thank you to the organizers and speakers for a well-curated programme that fostered collaboration and focused discussions at the intersection of health and AI. Meaningful connections and an exceptional city!

[Tamara Alagirova @TamaraAlagirova]

Wonderful to present our data at @escardio at one of the most important cardiology conferences in Madrid 🇪🇸 — over 33k+ participants from 150 countries! Grateful for our team’s contribution and inspiring connections. @society_eas #MoncyteHealth

[Simon Pfisterer @SimonPfisterer]

It was great to present our latest data at the #ESC Congress in #Madrid and to catch up with colleagues and friends at one of the most important cardiology conferences! Huge event with great science and clinical data + Madrid is nice! @society_eas

[Tamara Alagirova @TamaraAlagirova]

Join us at @escardio Congress in Madrid on 30 August, 13:15-14:00! Find out how alterations in cellular lipid metabolism link to outcomes of statin treatment & residual #cardiovascular risk - a step toward personalized cardiovascular care. 
#ESC2025 #highcholesterol

[Simon Pfisterer @SimonPfisterer]

It was very nice to record this podcast. Talking about our research at @helsinkiuni and forming the spin-out company https://t.co/ZeMLCOGrYi!

@TamaraAlagirova @helsinkiuni

[European Atherosclerosis Society @society_eas]

Dr @SimonPfisterer, Group Leader at the University of Helsinki and Chief Scientific Officer of Moncyte Ltd., was our guest in the latest episode of AtheroTalk. His work bridges cutting-edge research and clinical applications in dyslipidaemia and cardiovascular disease. We talk about his academic journey, his move into biotech, and his vision for the future of precision medicine in atherosclerosis.

🎧 Spotify: https://t.co/gQmEm80R43
🎧 Apple Podcasts: https://t.co/sMUVKvJCvx
🎧 Youtube: https://t.co/uIXm9VddV0 @ProfKausikRay @KatiOorni

[Christie Ballantyne @CBallantyneMD]

Fun discussion with @ErinMichos @smsaadatagah and Daniel Gaudet on a pragmatic approach to the patient with #chylomicronemia @nationallipid @ASPCardio @BCMHeart @BCMDeptMedicine @BCM_CVRI

[Simon Pfisterer @SimonPfisterer]

It was great to record an #AtheroTalk podcast and talk about our research and establishing the startup company https://t.co/ZeMLCOGrYi! A big thank you to the team, especially Sanne M. and @azinkh96 for interviewing me and doing the recording. It has been a very nice experience!

[azin kheirkhah @azinkh96]

Have you checked out the latest #AtheroTalk episode yet? 🎙️ It’s out now and worth a listen! @society_eas #academic #podcast
🎧 Spotify:
https://t.co/6NY4mWCSBL

[Simon Pfisterer @SimonPfisterer]

Thank you @MaxTamlander and @samrip for your help and contributions for the polygenic risk scores

[Simon Pfisterer @SimonPfisterer]

Extremely happy that our work got accepted in #ATVB! We functionally profiled 400 biobank samples, linking cellular lipid uptake, storage and handling to treatment outcomes of statin therapy and residual cardiovascular risk.
https://t.co/juNgqzoaVP

[Simon Pfisterer @SimonPfisterer]

The technology will be developed further by https://t.co/ZeMLCOGrYi to bring the first actionable diagnostic solution to dyslipidemia and cardiovascular disease, optimizing treatment selection and residual risk assessment.

@TamaraAlagirova @helsinkiuni

[Simon Pfisterer @SimonPfisterer]

This opens up large opportunities for novel precision medicine applications in dyslipidemia and cardiovascular disease.

[Simon Pfisterer @SimonPfisterer]

It has been a great pleasure to write this summary about new developments regarding LDL structure, function and cellular uptake, together with Gilles Lambert!
@CaixaResearch @helsinkiuni
@HiLIFE_helsinki #PerMedFH https://t.co/aTVjMK5STi

[Fausto Pinto @fjpinto1960]

Great start of our Horizon Europe project #FHEARLY with an outstanding group of colleagues @FUlisboa @LaleTokgozoglu @magdadaccord @SimonPfisterer @CROCETERA @MeralKayikcoglu

[Simon Pfisterer @SimonPfisterer]

@BNordestgaard Great achievement!

[Katariina Öörni @KatiOorni]

We wrote an editorial discussing the importance of the conformation of apoB. ApoB-100: The guardian of LDL stability - Atherosclerosis https://t.co/vJIi06k6ig
This editorial was insipired by an article published earlier in @ATHjournal
https://t.co/DGW9UWC1XO

[Tamara Alagirova @TamaraAlagirova]

Exciting news 🚀 MONCYTE Health joins EUR 7 million Horizon Europe funded international consortium for earlier diagnosis and management of Familial Hypercholesterolemia (FH)🔥

Full Press Release here: https://t.co/hFKN6FeWmR

[Simon Pfisterer @SimonPfisterer]

My followers dropped by 25% during the past 6 weeks. ➕ Content on this platform is getting increasingly difficult to enjoy. Checking out new options: https://t.co/cGUH82Wml4

[Simon Pfisterer @SimonPfisterer]

@TassulaPC Thank you @TassulaPC!

[Simon Pfisterer @SimonPfisterer]

Out now! We established a platform for functional characterization of gene variants, providing insight for 315 LDLR variants. Functional data improves cardiovascular risk assessment, going beyond "pathogenic" and "benign" groups. Important for #FH

https://t.co/RORf5cQvqI

[Simon Pfisterer @SimonPfisterer]

Extremely proud of my PhD student @majharulmamun who carried out most of this work and special thanks to our collaborators @samrip @MaxTamlander